Pay in 4 interest-free payments of $6.29 Learn more
Ships within 48 hours · Estimated delivery Oct 17 - Oct 22
To our knowledge, this is the first real-world study conducted in Turkey evaluating these two GLP-1 receptor agonists in a treatment-nave population over a 6-month period
19 This research culminated in the development of dapagliflozin, canagliflozin, and empagliflozin, which were approved by the FDA between 2013 and 2014 for the treatment of T2D
2d), and TAU (RR = 0.43, 95% CI 0.24
This development is expected to increase competition, improve affordability, and expand patient access to one of the worlds most in-demand therapeutic categories
S Choice
US$ 22.41
US$ 29.09
US$ 20.51
US$ 21.15
